KOL Views: What impact might Mitsubishi Tanabe’s Radicava have on ALS treatment and future R&D?

Mitsubishi Tanabe’s Radicava (edaravone) became just the second drug approved in the US for the treatment of amyotrophic lateral sclerosis (ALS) when the FDA gave the intravenous antioxidant a green light earlier this month. The decision was based on results from a Japanese Phase III trial in which patients experienced 33-percent less decline in physical function after six months relative to placebo. (See ViewPoints: Mitsubishi Tanabe playing a dangerous game with Radicava pricing.)

To provide FirstWord readers with a better understanding of how Radicava will impact the treatment paradigm for ALS, and what (if any) lessons can be gleaned for future therapeutic candidates, we are hosting an expert call with a key opinion leader this week.

Key topics that will be discussed during the call include, among other things… feedback on Radicava’s risk/benefit profile, level of enthusiasm for prescribing the drug; will the $145 000 annual price tag have any impact on if and how you use the agent; are all patients with ALS candidates for the therapy or are there subgroups that would be more ideal; does Radicava’s mechanism of action, or what is known about it anyway, offer any insights for future therapeutics; and are there any lessons to be learned from Mitsubishi Tanabe’s successful development programme for other ALS candidates; what compounds in or near human testing have demonstrated the most potential?

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the evolving treatment landscape for ALS.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.